Who Owns LeMaitre Vascular Company?

LeMaitre Vascular Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Controls LeMaitre Vascular?

Understanding the ownership structure of a company is crucial for investors and stakeholders alike, especially within the dynamic medical device industry. LeMaitre Vascular, a key player in the vascular device company market, presents a compelling case study. Knowing who owns LeMaitre Vascular company reveals insights into its strategic direction, governance, and potential for growth.

Founded in 1983, LeMaitre Vascular has evolved significantly, and its ownership has shifted alongside its growth. From its initial vision to its current status, the company's journey offers valuable company information. To gain a deeper understanding of LeMaitre Vascular's trajectory, explore its LeMaitre Vascular SWOT Analysis and uncover the key players shaping its future, from its leadership team to its diverse shareholder base, including LeMaitre Vascular investors.

LeMaitre Vascular, Inc., a prominent vascular device company, was established in 1983. Understanding the early ownership structure of the LeMaitre Vascular company is key to grasping its evolution. While specific details on the initial equity split among all founders aren't readily available in public filings, the influence of key figures is evident.

George W. LeMaitre has been a central figure in the LeMaitre Vascular company since its early days. He has served as the Chief Executive Officer and a member of the Board of Directors since 1992, and as Chairman since 2004. His long-standing leadership suggests a significant role in the company's ownership and strategic direction from its inception. The medical device industry is competitive, and LeMaitre Vascular's early ownership decisions likely shaped its trajectory.

Early ownership structures in the medical device industry often involve initial investments from founders, potentially supplemented by angel investors or contributions from friends and family. These early agreements usually include provisions such as vesting schedules to ensure founder commitment and buy-sell clauses to manage potential founder exits. Any initial ownership disputes or buyouts would have played a crucial role in shaping the distribution of control and reflecting the founding team's vision for the company's future. The company's Certificate of Incorporation, filed in Delaware, outlines the framework for its corporate governance, including provisions for the Board of Directors and stockholder voting, which would have been established during its early formation.

Key Aspects of Early Ownership

The early ownership of LeMaitre Vascular, like other companies in the medical device industry, involved pivotal decisions. These decisions set the foundation for the company's future direction and success. Understanding the initial ownership structure can provide insights into the company's strategic focus and growth trajectory. For more information on the company's growth, consider reading about the Growth Strategy of LeMaitre Vascular.

• Founder Involvement: George W. LeMaitre's continuous leadership indicates substantial founder ownership and influence.
• Legal Framework: The Certificate of Incorporation in Delaware outlines the governance structure established early on.
• Investment Sources: Early funding likely came from founders, possibly with angel investors or family contributions.
• Ownership Agreements: Vesting schedules and buy-sell clauses were likely part of the initial agreements.

LeMaitre Vascular SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The evolution of ownership for the LeMaitre Vascular company, a prominent vascular device company, reflects its growth and maturation within the medical device industry. Initially, ownership was likely more concentrated among founders and early investors. Over time, as the company expanded and went public, the ownership structure shifted to include a significant presence of institutional investors. This transition is typical for companies that experience substantial growth and seek access to capital markets.

The company's stock trades on Nasdaq under the symbol LMAT. As of June 6, 2025, the share price was $84.13, an increase of 8.58% from $77.48 on June 7, 2024. This indicates a positive trend in the company's financial performance, which often attracts institutional investors. The influx of institutional investors can lead to changes in company strategy and governance due to their influence through voting power and investment mandates. The shift towards a more institutionalized ownership structure is a key aspect of the LeMaitre Vascular company profile.

As of May 2025, key stakeholders include BlackRock, Inc., holding a significant number of shares. George W. LeMaitre, as an insider, held 1,891,310 shares, representing 8.37% of the company. This insider ownership, particularly by the Chairman and CEO, grants him considerable influence over company strategy and governance. The presence of institutional investors, such as BlackRock, and the insider ownership by key figures like George W. LeMaitre, shape the strategic direction of the company.

Key Ownership Insights

LeMaitre Vascular's ownership structure is primarily composed of institutional investors and insiders. The stock symbol for LeMaitre Vascular is LMAT.

• Institutional investors hold a significant portion of the company's stock.
• George W. LeMaitre, the Chairman and CEO, maintains a substantial insider ownership.
• The company's share price has shown positive growth, attracting investors.
• The company is a publicly traded vascular device company.

LeMaitre Vascular PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors of the LeMaitre Vascular company significantly influences its governance and is closely linked to its ownership structure. As of April 1, 2025, the leadership team includes key figures such as George W. LeMaitre, who has served as Chief Executive Officer and Board member since 1992, and Chairman since 2004. David B. Roberts, the company's President, and Martha Shadan, an independent director, also play crucial roles within the board.

At the 2025 Annual Meeting of Stockholders held on June 2, 2025, George W. LeMaitre, David B. Roberts, and Martha Shadan were elected as Class I directors for three-year terms. This composition reflects the ongoing management and oversight of the vascular device company. Understanding the board's composition is vital for anyone looking into LeMaitre ownership and its broader implications within the medical device industry.

The voting structure at LeMaitre Vascular generally operates on a one-share, one-vote basis. As of April 8, 2025, there were 22,594,362 shares of common stock entitled to vote for the 2025 Annual Meeting of Stockholders. George W. LeMaitre, as of December 31, 2024, controls approximately 8.5% of the outstanding common stock, which grants him significant influence over matters requiring stockholder approval. For more details on the company's financial operations, consider reading about the Revenue Streams & Business Model of LeMaitre Vascular.

Key Takeaways on LeMaitre Vascular's Board and Voting

The Board of Directors includes long-standing members, ensuring continuity in leadership.

• George W. LeMaitre holds significant voting power.
• Stockholders approved executive compensation on an advisory basis.
• Amendments to bylaws require a 75% vote unless the board recommends it.
• The company's structure is critical for understanding LeMaitre Vascular company information.

LeMaitre Vascular Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

In recent years, LeMaitre Vascular has shown consistent financial growth, influencing its ownership structure. For the year ending December 31, 2024, net sales grew by 14% to $219.9 million, up from $193.5 million in 2023. The company's robust financial position, with approximately $303 million in cash as of May 1, 2025, provides strategic flexibility.

Regarding shareholder returns, the Board of Directors approved a quarterly dividend of $0.20 per share on April 29, 2025, which was paid on May 29, 2025. This represents a 25% increase from the previous dividend approved in February 2025. Additionally, the company has authorized stock repurchase programs, including a current one for up to $75.0 million of common stock, set to conclude on February 17, 2026, unless extended. A previous repurchase program for up to $50.0 million was authorized in February 2024 and concluded on February 21, 2025. As of May 1, 2025, no shares had been repurchased under the new program.

Institutional investors hold a significant portion of LeMaitre Vascular's shares, with 90.16% ownership as of May 2025. While insider holdings slightly decreased to 9.64% in May 2025, major institutional holders such as BlackRock, Inc., Conestoga Capital Advisors, LLC, and Vanguard Group Inc. continue to maintain substantial stakes. The issuance of $172.5 million in Convertible Senior Notes due 2030 in December 2024 further reflects the company's financial strategy, with net proceeds of $167.7 million allocated for working capital and business development.

Key Development

Increased net sales by 14% to $219.9 million in 2024, indicating strong financial performance.

Ownership Trends

Institutional ownership remains high at 90.16% as of May 2025, with a slight decrease in insider holdings.

Financial Strategy

Issued $172.5 million in Convertible Senior Notes in December 2024 to support working capital and growth initiatives.

Shareholder Returns

Approved a quarterly dividend of $0.20 per share in April 2025, and authorized a $75.0 million stock repurchase program.

LeMaitre Vascular Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs